vs

Side-by-side financial comparison of Guardian Pharmacy Services, Inc. (GRDN) and MADRIGAL PHARMACEUTICALS, INC. (MDGL). Click either name above to swap in a different company.

Guardian Pharmacy Services, Inc. is the larger business by last-quarter revenue ($397.6M vs $321.1M, roughly 1.2× MADRIGAL PHARMACEUTICALS, INC.). Guardian Pharmacy Services, Inc. runs the higher net margin — 5.3% vs -18.2%, a 23.5% gap on every dollar of revenue.

CVS Pharmacy Inc. is an American retail corporation. A subsidiary of CVS Health, it is headquartered in Woonsocket, Rhode Island. Originally named the Consumer Value Stores, it was founded in Lowell, Massachusetts, in 1963.

Intercept Pharmaceuticals, Inc. is an American biopharmaceutical company incorporated in 2002, focusing on the development of novel synthetic bile acid analogs to treat chronic liver diseases, such as primary biliary cirrhosis (PBC) now called primary biliary cholangitis, non-alcoholic fatty liver disease, cirrhosis, portal hypertension, primary sclerosing cholangitis and also the intestinal disorder, bile acid diarrhea.

GRDN vs MDGL — Head-to-Head

Bigger by revenue
GRDN
GRDN
1.2× larger
GRDN
$397.6M
$321.1M
MDGL
Higher net margin
GRDN
GRDN
23.5% more per $
GRDN
5.3%
-18.2%
MDGL

Income Statement — Q4 FY2025 vs Q4 FY2025

Metric
GRDN
GRDN
MDGL
MDGL
Revenue
$397.6M
$321.1M
Net Profit
$20.9M
$-58.6M
Gross Margin
21.5%
Operating Margin
7.7%
-18.6%
Net Margin
5.3%
-18.2%
Revenue YoY
210.8%
Net Profit YoY
1.4%
EPS (diluted)
$-2.55

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
GRDN
GRDN
MDGL
MDGL
Q4 25
$397.6M
$321.1M
Q3 25
$377.4M
$287.3M
Q2 25
$344.3M
$212.8M
Q1 25
$329.3M
$137.3M
Q4 24
$103.3M
Q3 24
$314.4M
$62.2M
Q1 24
$0
Q4 23
$0
Net Profit
GRDN
GRDN
MDGL
MDGL
Q4 25
$20.9M
$-58.6M
Q3 25
$9.8M
$-114.2M
Q2 25
$9.0M
$-42.3M
Q1 25
$9.4M
$-73.2M
Q4 24
$-59.4M
Q3 24
$-122.0M
$-107.0M
Q1 24
$-147.5M
Q4 23
$-112.2M
Gross Margin
GRDN
GRDN
MDGL
MDGL
Q4 25
21.5%
Q3 25
19.8%
Q2 25
19.8%
Q1 25
19.5%
96.7%
Q4 24
Q3 24
19.4%
Q1 24
Q4 23
Operating Margin
GRDN
GRDN
MDGL
MDGL
Q4 25
7.7%
-18.6%
Q3 25
4.3%
-39.7%
Q2 25
3.7%
-22.2%
Q1 25
3.9%
-57.8%
Q4 24
-64.8%
Q3 24
-33.3%
-187.1%
Q1 24
Q4 23
Net Margin
GRDN
GRDN
MDGL
MDGL
Q4 25
5.3%
-18.2%
Q3 25
2.6%
-39.8%
Q2 25
2.6%
-19.9%
Q1 25
2.9%
-53.4%
Q4 24
-57.5%
Q3 24
-38.8%
-172.0%
Q1 24
Q4 23
EPS (diluted)
GRDN
GRDN
MDGL
MDGL
Q4 25
$-2.55
Q3 25
$-5.08
Q2 25
$-1.90
Q1 25
$-3.32
Q4 24
$-2.50
Q3 24
$-4.92
Q1 24
$-7.38
Q4 23
$-5.73

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
GRDN
GRDN
MDGL
MDGL
Cash + ST InvestmentsLiquidity on hand
$65.6M
$198.7M
Total DebtLower is stronger
$0
$339.9M
Stockholders' EquityBook value
$217.9M
$602.7M
Total Assets
$412.7M
$1.3B
Debt / EquityLower = less leverage
0.00×
0.56×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
GRDN
GRDN
MDGL
MDGL
Q4 25
$65.6M
$198.7M
Q3 25
$36.5M
$295.7M
Q2 25
$18.8M
$186.2M
Q1 25
$14.0M
$183.6M
Q4 24
$100.0M
Q3 24
$37.2M
$232.7M
Q1 24
$622.5M
Q4 23
$99.9M
Total Debt
GRDN
GRDN
MDGL
MDGL
Q4 25
$0
$339.9M
Q3 25
$339.8M
Q2 25
$118.4M
Q1 25
$118.0M
Q4 24
$117.6M
Q3 24
$34.3M
$117.1M
Q1 24
$116.1M
Q4 23
$115.5M
Stockholders' Equity
GRDN
GRDN
MDGL
MDGL
Q4 25
$217.9M
$602.7M
Q3 25
$195.5M
$625.7M
Q2 25
$179.7M
$696.0M
Q1 25
$163.2M
$710.6M
Q4 24
$754.4M
Q3 24
$133.9M
$777.2M
Q1 24
$850.8M
Q4 23
$405.3M
Total Assets
GRDN
GRDN
MDGL
MDGL
Q4 25
$412.7M
$1.3B
Q3 25
$390.0M
$1.4B
Q2 25
$356.3M
$1.0B
Q1 25
$334.0M
$996.6M
Q4 24
$1.0B
Q3 24
$348.0M
$1.1B
Q1 24
$1.1B
Q4 23
$640.5M
Debt / Equity
GRDN
GRDN
MDGL
MDGL
Q4 25
0.00×
0.56×
Q3 25
0.54×
Q2 25
0.17×
Q1 25
0.17×
Q4 24
0.16×
Q3 24
0.26×
0.15×
Q1 24
0.14×
Q4 23
0.28×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
GRDN
GRDN
MDGL
MDGL
Operating Cash FlowLast quarter
$34.6M
$-133.5M
Free Cash FlowOCF − Capex
$-133.8M
FCF MarginFCF / Revenue
-41.7%
Capex IntensityCapex / Revenue
0.1%
Cash ConversionOCF / Net Profit
1.65×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
GRDN
GRDN
MDGL
MDGL
Q4 25
$34.6M
$-133.5M
Q3 25
$28.2M
$79.8M
Q2 25
$19.9M
$-47.1M
Q1 25
$17.6M
$-88.9M
Q4 24
$-104.5M
Q3 24
$-67.0M
Q1 24
$-149.2M
Q4 23
$-79.9M
Free Cash Flow
GRDN
GRDN
MDGL
MDGL
Q4 25
$-133.8M
Q3 25
$24.2M
$79.0M
Q2 25
Q1 25
Q4 24
$-104.7M
Q3 24
$-67.8M
Q1 24
$-149.5M
Q4 23
$-81.0M
FCF Margin
GRDN
GRDN
MDGL
MDGL
Q4 25
-41.7%
Q3 25
6.4%
27.5%
Q2 25
Q1 25
Q4 24
-101.3%
Q3 24
-109.0%
Q1 24
Q4 23
Capex Intensity
GRDN
GRDN
MDGL
MDGL
Q4 25
0.1%
Q3 25
1.1%
0.3%
Q2 25
0.0%
Q1 25
0.0%
Q4 24
0.2%
Q3 24
1.3%
Q1 24
Q4 23
Cash Conversion
GRDN
GRDN
MDGL
MDGL
Q4 25
1.65×
Q3 25
2.87×
Q2 25
2.21×
Q1 25
1.86×
Q4 24
Q3 24
Q1 24
Q4 23

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

GRDN
GRDN

Segment breakdown not available.

MDGL
MDGL

Rebates Customer Fees Credits Co Pay Assistance And Other$208.5M65%
Other$76.0M24%
Chargebacks Discounts For Prompt Pay And Other Allowances$36.6M11%

Related Comparisons